Noninvasive stool antigen assay can effectively screen Helicobacter pylori infection and assess success of eradication therapy in hemodialysis patients

Wang, Yen-Lin; Sheu, Bor–Shyang; Huang, Jeng-Jong; Yang, Haw‐Ching

doi:10.1053/ajkd.2001.25200

Cited by 38 publications

(48 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current authors surveyed and summarized the previous studies that studied the prevalence of H. pylori infection in patients receiving hemodialysis (see Table 1). [12,[18][19][20][21][22][23][24][25][26][27][28] In the present study, 40.3% of hemodialysis patients were infected with H. pylori. Considering that the prevalence of H. pylori infection has been reported to be higher than 70% among Japanese adults over 50 years of age, [29] these results indicate the relative percentage of H. pylori-positive hemodialysis patients could be lower than the general patient population.…”

Section: Discussionsupporting

confidence: 47%

Eradication ofHelicobacter pyloriin Hemodialysis Patients

et al. 2007

View full text Add to dashboard Cite

Background. Helicobacter pylori (H. pylori) are a causative agent of digestive disease. Although a proton pump inhibitor combined with amoxicillin-clarithromycin is the accepted drug treatment for H. pylori eradication in Japan, there is no consensus treatment for hemodialysis patients. Study. Seventy-seven hemodialysis patients underwent upper digestive tract endoscopy. Biopsy specimens were taken, and histological findings, culture, and rapid urease tests were performed to confirm the presence of H. pylori. H. pylori-positive patients were then administered at random either a seven-day lansoprazole (60 mg a day)-amoxicillin (750 mg a day)-clarithromycin (400 mg a day) (LAC) regimen or a seven-day lansoprazole (60 mg a day)-clarithromycin (400 mg a day) (LC) regimen. The success of H. pylori eradication was determined from histological findings, culture, and rapid urease tests. Results. In 13 of 77 patients (13.6%), ulcers and/or ulcer scars were seen by endoscopy. Thirty-one patients (40.3%) were positive for H. pylori, and 20 patients among them were randomized to one of two regimens: one is seven-day LAC regimen (eleven patients) and the other is seven-day LC regimen (nine patients). Eradication was successful in nine of the eleven patients (72.7%) receiving the LAC regimen, but in only three of the nine patients (33.3%) who underwent the LC regimen. No serious adverse effects were observed with either regimen, and 95% of the patients reported complete compliance. Conclusion. A seven-day low dose LAC regimen is safe and effective and recommended for treatment of H. pylori infection in hemodialysis patients.

show abstract

Section: Discussionsupporting

confidence: 47%

Eradication ofHelicobacter pyloriin Hemodialysis Patients

et al. 2007

View full text Add to dashboard Cite

show abstract

“…However, Wang et al [27] proposed that stool antigen is a noninvasive and reliable tool for screening H. pylori infections before therapy and assessing the success of eradication therapy in patients with ESRD. Establishing the reliability of diagnostic methods for H. pylori is crucial for managing infection [28] .…”

Section: H Pylori Tests For Patients With End-stage Renal Diseasementioning

confidence: 99%

“…Few studies concerning triple therapy in uremic patients have been reported [27,[35][36][37][38][39] . A 1-wk course of PPI-based triple therapy (omeprazole, 20 mg twice daily; amoxicillin, 1 g twice daily; and clarithromycin, 500 mg twice daily) achieved a high eradication rate of H. pylori infection in patients with CRF and a creatinine clearance (CrCl) of less than 30 mL/ min per 1.73 m 2 , similar to that of controls with normal renal function [35] .…”

Section: H Pylori Therapy In Patients With End-stage Renal Diseasementioning

confidence: 99%

“…Amoxicillin [41] and clarithromycin [42] , which are primarily eliminated renally, necessitate dosage reduction in patients with renal impairment according to CrCl. Wang et al [27] used 7-d triple therapy with omeprazole (20 mg twice daily), amoxicillin (1 g twice daily), and clarithromycin (500 mg twice daily) and reported an eradication rate of 86.8% among 40 hemodialysis patients. Tsukada et al [38] reported an eradication rate of 82.0% among 39 hemodialysis patients using 7-d triple therapy with omeprazole (30 mg twice daily), amoxicillin (500 mg twice daily), and clarithromycin (400 mg twice daily).…”

Section: H Pylori Therapy In Patients With End-stage Renal Diseasementioning

confidence: 99%

See 1 more Smart Citation

Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens

Chang¹,

Hu²

2015

WJGPT

View full text Add to dashboard Cite

show abstract

“…Currently, the regimen most commonly recommended for first line treatment of H. pylori in patients with normal renal function is a triple therapy with a proton pump inhibitor (PPI) (e.g., omeprazole 20 mg twice daily), amoxicillin (1 g twice daily), and clarithromycin (500 mg twice daily) for 10-14 days [4,6]. However, the optimal therapeutic regimen for H. pylori infection has not yet been defined in uremic patients, especially in ESRD patients receiving chronic hemodialysis, although a few studies concerning triple therapy in uremic patients have been reported [5,[7][8][9][10][11]. Because the ideal treatment regimen should be not only effective, but also simple and safe, higher efficacy and fewer adverse effects with excellent compliance are vital concerns in the eradication of H. pylori infection in hemodialysis patients.…”

Section: Introductionmentioning

confidence: 99%